Objective-␥Ј fibrinogen is a newly emerging biomarker that is associated with cardiovascular disease (CVD). However, the genetic determinants of ␥Ј fibrinogen levels are unknown. We therefore conducted a genome-wide association study on 3042 participants from the Framingham Heart Study Offspring Cohort. Methods and Results-A genome-wide association study with 2.5 million single-nucleotide polymorphisms (SNPs) was carried out for ␥Ј fibrinogen levels from the cycle 7 examination. Fifty-four SNPs in or near the fibrinogen gene locus demonstrated genome-wide significance (PϽ5.0ϫ10 Ϫ8 ) for association with ␥Ј fibrinogen levels. The top-signal SNP was rs7681423 (Pϭ9.97ϫ10 Ϫ110 ) in the fibrinogen gene locus near FGG, which encodes the ␥ chain. Conditional on the top SNP, the only other SNP that remained genome-wide significant was rs1049636. Associations between SNPs, ␥Ј fibrinogen levels, and prevalent CVD events were examined using multiple logistic regression. ␥Ј fibrinogen levels were associated with prevalent CVD (Pϭ0.02), although the top 2 SNPs associated with ␥Ј fibrinogen levels were not associated with CVD. These findings contrast those for total fibrinogen levels, which are associated with different genetic loci, particularly FGB, which encodes the B␤ chain. Conclusion-␥Ј fibrinogen is associated with prevalent CVD and with SNPs exclusively in and near the fibrinogen gene locus. (Arterioscler Thromb Vasc Biol. 2011;31:2345-2352.)
␥Ј fibrinogen is an alternatively spliced form of the clotting factor fibrinogen ( Figure 1 ) that has shown an association with arterial thrombosis and venous thrombosis in case-control studies. [1] [2] [3] [4] [5] Total fibrinogen is itself a wellvalidated risk factor for cardiovascular disease (CVD). 6 Fibrinogen is a disulfide-bonded dimer, with each half of the dimer containing 1 A␣ chain, 1 B␤ chain, and 1 ␥ chain, which can be either the more common ␥A chain or a ␥Ј chain. ␥Ј fibrinogen consists of approximately 90% heterodimers containing 1 ␥Ј chain and 1 ␥A chain, and Ϸ10% homodimers containing 2 ␥Ј chains. ␥Ј fibrinogen constitutes Ϸ7% of total fibrinogen levels, 2, 3, 7 although the amount varies considerably among individuals, particularly under pathological conditions. 8, 9 Unlike many CVD risk markers, ␥Ј fibrinogen has biochemical properties that have the potential to actually contribute to the etiology of CVD. In particular, compared with total fibrinogen, ␥Ј fibrinogen forms fibrin blood clots that show differences in clot architecture, 10, 11 are mechanically stiffer, 12 and are resistant to fibrinolysis. [12] [13] [14] These properties have been hypothesized to contribute in a causative way to thrombosis, 15 although this is an area of ongoing controversy. 16 In previous case-control studies, elevated ␥Ј fibrinogen levels have been associated with arterial thrombosis, including myocardial infarction, 1,3 coronary artery disease, 2 and stroke. 4, 5 But paradoxically, ␥Ј fibrinogen levels have been inversely associated with venous thrombosis 17 and thrombotic microangiopathy. 18 The reasons behind these differences are still unclear and may be the result of genetic variation or the design of previous studies. The genetic determinants of ␥Ј fibrinogen levels have not been fully investigated, which provided the impetus for the present studies. In addition, previous epidemiological studies on ␥Ј fibrinogen have used a case-control design, which is more susceptible to various forms of bias. 19 The association between ␥Ј fibrinogen and CVD has not been investigated in a large community-based cohort to date. The present study was therefore undertaken to investigate the association between ␥Ј fibrinogen, genetic determinants, and CVD in a well-characterized cohort, the Framingham Offspring Study.
Methods

Study Population
We conducted an analysis of ␥Ј fibrinogen concentrations in stored blood specimens from subjects enrolled in the Framingham Off-spring Study. The design and methodology of this study for the long-term evaluation of risk factors for CVD have been described previously. 20 Briefly, 5124 offspring and the spouses of the offspring of the original Framingham cohort members, 5 to 70 years of age at entry, were enrolled and provided baseline data. 21 Participants had completed 7 examinations, including a blood draw, over intervals of 4 to 6 years and were followed for CVD morbidity and mortality. Plasma samples from 3300 individuals available from the seventh examination cycle (1998 to 2001) were obtained for measuring ␥Ј fibrinogen levels. Total fibrinogen levels had been measured in a previous study. 22 The subjects gave informed consent, and the study was approved by the relevant institutional review boards. Aliquots were frozen at Ϫ20°C after the initial phlebotomy at the time of the baseline examination.
␥ Fibrinogen Assay
␥Ј fibrinogen was assayed using an ELISA protocol described previously. 7 The precision and variability of this assay have been validated. 7 The ELISA coefficient of variability was 9.3% at the mean ␥Ј fibrinogen level.
Genotyping and Samples for Genome-Wide Association Study
DNA samples from 9274 Framingham Heart Study 3-generation participants were genotyped using the Affymetrix 500K mapping array and the Affymetrix 50K supplemental array. Of those, 8481 samples were genotyped successfully (sample call rate Ն97%) and had person heterozygosity within ؎5 standard deviations from the mean. Of these, 3042 had complete data on ␥Ј fibrinogen values and other key covariates and were included in the subsequent genome-wide association analyses. A total of 549 781 single-nucleotide polymorphisms (SNPs) were genotyped. Of those, 503 551 were genotyped successfully with a call rate Ͻ95% or Hardy-Weinberg equilibrium probability value of Ͻ10 Ϫ6 . Imputation of 2.5 million autosomal SNPs in HapMap based on successfully genotyped SNPs from the chips and phased chromosomes for 60 HapMap CEU founders was conducted using a Hidden Markov Model algorithm implemented in the MACH software (http://www.sph.umich.edu/csg/abecasis/MACH/index.html).
Genome-Wide Association Analyses
To adjust for potential population stratification, principal components of the genotypes of directly genotyped SNPs were computed using the Eigenstrat software. 23 The first 10 principal components were included as covariates in addition to sex, age, body mass index (BMI), fasting blood glucose, systolic blood pressure, diabetes, smoking status, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides in the association analyses with each of the 2.5 million imputed SNPs. We used, in the association analyses, a linear mixed-effects model with a fixed additive genotype effect and subject specific random effects that are correlated within family with correlation proportional to kinship coefficients between family members. 24
Determination of Risk Factors and Prevalent CVD
All visits preceding and including the seventh examination cycle included assessment of the prevalence of CVD and evaluation of CVD risk factors. Cases of myocardial infarction and stroke, as well as related end points, such as angina, coronary insufficiency, and transient ischemic attack, were adjudicated by a 3-physician end point review committee. Prevalent "hard CVD" events that occurred before the seventh examination consisted of the prior occurrence of myocardial infarction or coronary insufficiency. Prevalent "total CVD" consisted of the prior occurrence of either one of the CVD events listed above or angina pectoris, transient ischemic attack, stroke, or intermittent claudication. Specific criteria for the clinical and laboratory methods and the CVD event adjudication have been published previously. 21, 25 During the seventh clinical examination cycle, information was obtained on cigarette smoking during the past year and use of medications. Blood pressure after sitting for 5 minutes was measured using standardized methods. Phlebotomy took place under fasting conditions. Lipid determinations were made at the time of the seventh examination cycle in the Framingham Heart Study laboratory. Plasma cholesterol was measured according to the Lipid Research Clinics Program Protocol, and HDL cholesterol was determined after precipitation of non-HDL lipoproteins with heparin-manganese. 26 
Relating ␥ Fibrinogen Levels and Identified SNPs to Prevalent Cardiovascular Events
The difference in the distribution of each of prevalent CVD and myocardial infarction across ␥Ј fibrinogen tertiles was assessed using logistic regression adjusting for sex, age, BMI, systolic blood pressure, diabetes mellitus, smoking, total cholesterol, HDL cholesterol, and triglycerides. The association between ␥Ј fibrinogen and risk of prevalent CVD and myocardial infarction were estimated using unconditional logistic regression. All variables independently associated with CVD or with ␥Ј fibrinogen at PϽ0.05 were considered as potential confounders in the final model.
Results
Study Sample Characteristics
Descriptive statistics (meanϮstandard deviation for continuous risk factors, count, and percentage of prevalence for The current hypothesis is that competition between spliceosome cleavage of intron 9, which removes the intron and generates the ␥A mRNA, vs polyadenylation within intron 9 at the AAUAAA site that cleaves off the 3Ј end of the pre-mRNA to generate the ␥Ј mRNA, regulates the ratio of ␥A to ␥Ј mRNA.
dichotomous risk factors and ␥Ј and total fibrinogen) are presented in Table 1 .
Genome-Wide Association Study
To identify genetic loci related to ␥Ј fibrinogen levels, we conducted a genome-wide association study (GWAS).
Quantile-quantile plots of the observed versus expected probability values showed little evidence of potential inflation in the results, with a genomic control value of 1.01. A total of 54 SNPs exceeded the threshold for genome-wide significance (PϽ5.0ϫ10 Ϫ8 ) and clustered exclusively in or near the fibrinogen gene locus on chromosome 4 ( Figure 2 ). No other loci on other chromosomes reached the threshold for significance. The strongest statistical evidence for an association with ␥Ј fibrinogen levels was with rs7681423 (minor allele frequency [MAF]: 0.227, Pϭ9.97ϫ10 Ϫ110 , variance explained: 13%), which is 8.35 kb upstream of the ␥ chain gene FGG (Table 2; Figure 3 ). Interestingly, the AϾG variant in FGB with the strongest statistical association with total fibrinogen levels, rs1800789, 27 was not significantly associated with ␥Ј fibrinogen levels (MAF: 0.209, Pϭ4.34ϫ10 Ϫ4 , variance explained: 0.4%).
Several SNPs in FGG were identified by genome-wide association that have previously been associated with ␥Ј fibrinogen levels, particularly rs1049636, 3 the 9340CϾT variant within intron 9 (MAF: 0.319, Pϭ3.84ϫ10 Ϫ50 , R 2 ϭ0.13 with rs7681423). In addition, rs2066861, the 7874GϾA variant in intron 8 (MAF: 0.227, Pϭ1.90ϫ10 Ϫ109 , R 2 ϭ1.0 with rs7681423); rs2066864, the 9615CϾT variant in intron 9 (MAF: 0.227, Pϭ5.38ϫ10 Ϫ109 , R 2 ϭ1.0 with rs7681423); and rs2066865, the 10 034CϾT variant in the 3Ј untranslated region (MAF: 0.225, Pϭ7.13ϫ10 Ϫ109 , R 2 ϭ1.0 with rs7681423), which have previously been shown to be in linkage disequilibrium, 17 were associated with ␥Ј fibrinogen levels. We performed additional GWAS, sequentially adjust- ing for top signal SNPs from the previous GWAS. After adjusting for the top signal SNP rs7681423 from the initial GWAS, rs1049636 became the top signal SNP (Pϭ3.4ϫ10 Ϫ17 , variance explained: 1.8%), and all aforementioned SNPs were no longer genome-wide significant. After additionally adjusting for rs1049636, no genome-wide significant signal remained (Supplemental Table I , available online at http://atvb.ahajournals.org). Perhaps the most intriguing association with SNPs near the fibrinogen gene locus was in the PLRG1 gene near the fibrinogen gene locus; rs12642770 (MAF: 0.205, Pϭ8.69ϫ10 Ϫ30 , 81 kb from the top SNP rs7681423, R 2 ϭ0.35 with rs7681423), rs12645631 (MAF: 0.147, Pϭ2.77ϫ10 Ϫ9 , R 2 ϭ0.09 with rs7681423), and rs7698829 (MAF: 0.147, Pϭ2.81ϫ10 Ϫ9 , R 2 ϭ0.06 with rs7681423) in PLRG1 all showed genome-wide significance. PLRG1 encodes pleiotropic regulator 1, which plays a direct role in mRNA splicing. 28 No SNPs in PLRG1 were found previously in association with total fibrinogen levels. 27 Because the ␥Ј chain arises from an alternative mRNA splicing event, 29, 30 this raises the intriguing possibility that SNPs in PLRG1 may play a functional role in modulating ␥Ј fibrinogen levels. After adjusting for the top signal SNP rs7681423 in FGG, however, these SNPs were no longer genome-wide significant (P ranged from 0.01 to 0.19); after additional adjusting for rs1049636, the associations of these SNPs were further weakened (P ranged from 0.17 to 0.27), which suggests that association signals observed in PLRG1 may be attributable to linkage disequilibrium (Supplemental Table I ).
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Association Between SNPs and CVD
The 2 independent top signal SNPs, rs7681423 and rs1049636, near and in FGG were not associated with any of the cardiovascular events examined in this study (Table 3) , but the effects were directionally consistent with their association with ␥Ј fibrinogen. The previously identified top signal SNP for total fibrinogen, rs1800789, was not associated with any of the cardiovascular events either, 27 even though total fibrinogen levels are well known to be associated with CVD. 6
Association Between ␥ Fibrinogen Levels and CVD
␥Ј fibrinogen has previously been shown to be significantly associated (all PϽ0.05) with the cardiovascular risk factors of age, sex, BMI, smoking, diabetes, blood glucose, and triglycerides and inversely associated with HDL cholesterol in this cohort. 7 Individuals with prevalent CVD had significantly higher risk-factor adjusted mean (Ϯstandard error) ␥Ј fibrinogen concentrations than those without CVD (0.278Ϯ0.006 mg/mL versus 0.258Ϯ0.002 mg/mL; Pϭ0.002). Results were similar for men and women separately (sex-by-prevalent-CVD probability valueϭ0.220). In a cross-sectional assessment of the relationship between ␥Ј fibrinogen and CVD, the odds ratio (OR) of event per 0.1 mg/mL increase in ␥Ј fibrinogen was 1.12 (1.03 to 1.21) after adjustment for sex, age, BMI, systolic blood pressure, fasting blood glucose, diabetes mellitus, smoking, total cholesterol, HDL cholesterol, and triglycerides. In a univariate model, the age-adjusted OR (95% confidence interval) comparing the prevalence of CVD in the highest versus lowest ␥Ј fibrinogen tertile was 1.84 (1.15 to 2.93) for women, 1.70 (1.19 to 2.43) for men, and 1.76 (1.33 to 2.34) for men and women combined. This association (Table 4 ) remained significant after multivariable adjustment for sex, age, BMI, smoking, diabetes, fasting blood glucose, systolic blood pressure, total cholesterol, HDL The association between ␥Ј fibrinogen and stroke (multivariable adjusted OR 1.42 [0.68 to 2.95]) did not reach statistical significance (Pϭ0.36), although there was a nonsignificant trend toward higher ␥Ј levels with stroke. For all CVD outcomes, there was no significant ␥Ј fibrinogen-by-sex interaction on associations with prevalent CVD (Pϭ0.082 for hard CVD, Pϭ0.270 for myocardial infarction, Pϭ0.335 for stroke).
Further adjustment for total fibrinogen rendered nonsignificant associations of ␥Ј fibrinogen with CVD (PϾ0.05 for men and women combined). This is in part due to the correlation between the 2 fibrinogen measurements (age-and sex-adjusted Pearson correlation coefficient of 0.44; PϽ0.001). However, in multivariable-adjusted models (Table  4) , the OR for the highest versus lowest tertile of ␥Ј fibrinogen alone for CVD was 1.53 (1.14 to 2.05) and for the highest versus lowest tertile of total fibrinogen alone, it was 1.54 (1.14 to 2.07), but the OR for the highest tertile of both total fibrinogen and ␥Ј fibrinogen compared with the lowest tertile of both was 2.17 (1.42 to 3.32). The OR for association between fibrinogen and myocardial infarction was also increased when considering both ␥Ј fibrinogen and total fibrinogen simultaneously than when considering either type of fibrinogen alone. In multivariable-adjusted models, the OR for highest versus lowest tertile of ␥Ј fibrinogen alone was 1.76 (1.06 to 2.92), and for the highest versus lowest tertile of total fibrinogen alone, it was 1.99 (1.21 to 3.28), but the OR for the highest tertile versus the lowest tertile of both total fibrinogen and ␥Ј fibrinogen was 3.08 (1.41 to 6.72). These results suggest that ␥Ј and total fibrinogen are not simply surrogate markers for one another but have different associations with CVD. In addition, adjusting for the top signal SNPs rs7681423 and rs1049636 of ␥Ј fibrinogen and rs1800789 of total fibrinogen levels resulted in minimal changes to these results ( Supplemental Tables II and III) .
Taken together, these results suggest that genetics may not play a major role in the association between ␥Ј fibrinogen and CVD. Because ␥Ј fibrinogen is an acute phase reactant that increases in response to inflammation, 8, 9 environmental factors may play a greater role than genetic factors in its association with CVD. 
Discussion
The genetic loci associated with total fibrinogen levels 27 are different from those associated with ␥Ј fibrinogen levels in the current study. For total fibrinogen, 4 loci are marked by 1 or more SNPs with genome-wide significance (PϽ5.0ϫ10 Ϫ8 ); FBG, the fibrinogen B␤ chain gene; IRF1, the interferon regulatory factor 1 gene; PCCB, the propionyl coenzyme A carboxylase gene; and NLRP3, the NLR family pyrin domain containing 3 isoforms gene. In contrast, the loci we identified that are significantly associated with ␥Ј fibrinogen levels are all located in or near the fibrinogen gene locus, including the PLRG1 gene.
Some of the SNPs in the ␥ gene FGG have been previously associated with ␥Ј fibrinogen levels. In particular, rs1049636, the 9340CϾT variant within intron 9 has been shown to be significantly associated with ␥Ј fibrinogen levels. 3 Individuals in the Stockholm Coronary Artery Risk Factor study homozygous for the 9340T variant had a lower mean ␥Ј fibrinogen level (0.25 mg/mL for cases, 0.21 mg/mL for controls) compared with those homozygous for the 9340C variant (0.38 mg/mL for cases, 0.31 mg/mL for controls), whereas heterozygotes displayed intermediate levels (0.29 mg/mL for cases, 0.27 mg/mL for controls). In addition, rs2066861, the 7874GϾA variant in intron 8, rs2066864, the 9615CϾT variant in intron 9, and rs2066865, the 10 034CϾT variant in the 3Ј untranslated region, which are in linkage disequilibrium and are haplotype-tagging SNPs, have been associated with ␥Ј fibrinogen levels. 17 Perhaps the most intriguing association with SNPs near the fibrinogen gene locus is in the PLRG1 gene next to the fibrinogen gene locus; rs12642770, rs12645631, and rs7698829 in PLRG1 all showed genome-wide significance. None of these SNPs are significantly associated with total fibrinogen levels. 27 PLRG1 encodes pleiotropic regulator 1, which plays a direct role in mRNA splicing. 28 This raises the possibility that PLRG1 may be mechanistically involved in modulating the splicing events that give rise to the ␥Ј and ␥A splice variants. 29, 30 However, it is also possible that the PLRG1 SNPs are simply in linkage disequilibrium with other functional SNPs within the fibrinogen locus that constitute a specific haplotype. However, the minor allele frequencies of rs12645631 and rs7698829 in the PLRG1 locus, 0.14, are different from the MAF of rs1049636 in FGG intron 9 (0.32); the estimated R 2 with the 2 PLRG1 SNPs was 0.25 and different from the minor allele frequencies of 0.224 to 0.225 for the H2H2 haplotype-tagging SNPs rs2066861, rs2066864, and rs2066865 (estimated R 2 between each of the tagging SNPs and each of the 2 PLRG1 loci was only 0.04) that have been associated with ␥Ј fibrinogen levels previously. 17 On the other hand, the MAF of rs12642770 in the PLRG1 locus, 0.21, is similar to those of the H2H2 haplotype-tagging SNPs (estimated R 2 between each of the tagging SNPs and rs12642770 was 0.36). Additional studies will be required to determine whether the PLRG1 locus plays a functional role in ␥Ј fibrinogen regulation.
Of interest, the top SNP in the fibrinogen gene cluster that was reported in association with total fibrinogen levels was not associated with ␥Ј fibrinogen levels. The strongest statistical evidence for an association with total fibrinogen levels was with rs1800789, 27 which is located in exon 7 of the fibrinogen B␤ chain gene FGB; the association of this SNP with ␥Ј fibrinogen levels did not even reach statistical significance (Pϭ4.34ϫ10 Ϫ4 ). Rather, the top SNP in association with ␥Ј fibrinogen levels was rs7681423, 8.35 kb upstream of the ␥ chain gene FGG. These findings suggest that ␥Ј fibrinogen and total fibrinogen levels are under differential genetic control, consistent with the partially additive ORs for CVD observed in Table 4 .
The results of the present study show a significant increased multivariable-adjusted association of plasma ␥Ј fibrinogen with prevalent total CVD, as well as prevalent myocardial infarction. The association was not as robust as was seen in our previous case-control study of acute coronary artery disease, which showed an OR of 7.16 comparing the top and bottom ␥Ј fibrinogen quartiles. 2 However, although the Framingham Offspring Study participants in the present study had no documented history of CVD, it is likely that some of the participants may have had underlying subclinical CVD that had not yet manifested itself as an acute event. In addition, the time since the onset of CVD varied widely among the Framingham Offspring cohort, whereas our previous case-control study examined acute coronary artery disease at the time of diagnosis.
In addition, there was a higher order interaction between ␥Ј fibrinogen and total plasma fibrinogen that manifested as a further increased association with myocardial infarction ( Table 4 ). However, further adjustment for total fibrinogen attenuated the statistical significance of the association between ␥Ј fibrinogen and CVD. This is to be expected, because ␥Ј fibrinogen is a subset of total fibrinogen. By analogy, low-density lipoprotein cholesterol levels, a subset of total cholesterol, lose significant association with CVD if adjusted for total cholesterol levels. However, in addition, variables that affect total fibrinogen expression may also affect ␥Ј fibrinogen expression. As an example, the FGG T9430C polymorphism in the fibrinogen ␥ gene promoter, rs1049636, which increases total fibrinogen concentration, is also associated with increased plasma ␥Ј fibrinogen concentration. 3 Thus, although there is significant correlation between total fibrinogen and ␥Ј fibrinogen, there is also considerable interindividual variation between these 2 biomarkers. 2, 7, 9 The partially additive effect of ␥Ј and total fibrinogen on the ORs for CVD indicates that ␥Ј and total fibrinogen are not simply surrogates for one another. Another finding suggesting that ␥Ј and total fibrinogen are not surrogate markers comes from the GWAS, in which different SNPs are associated with ␥Ј and total fibrinogen levels.
It remains to be seen whether or not ␥Ј fibrinogen is simply a marker of CVD or a prospectively defined risk factor for CVD. However, the data presented here provide a compelling rationale for further investigation into the association between ␥Ј fibrinogen and CVD. Future prospective studies are therefore warranted to examine the ability of ␥Ј fibrinogen to predict CVD. 
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